Press Releases Alvotech Nyse

Equities

ALVO

LU2458332611

Real-time Estimate Cboe BZX Other stock markets 09:30:07 2024-05-01 am EDT			5-day change	1st Jan Change
14.51 ^USD	+0.07%		+8.21%	+54.58%

Apr. 30	Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	MT
Apr. 30	Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alvotech - U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-FreeInterchangeable Biosimilar to Humira	07:29am	AQ
Alvotech And Teva's Selarsdi™ (ustekinumab-aekn), Biosimilar To Stelara® Approved By FDA	02:17am	AQ
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)	Apr. 30	GL
FDA Approval Of Alvotech/Teva Ustekinumab Biosimilar	Apr. 26	AQ
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi	Apr. 25	AQ
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)	Apr. 24	GL
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira	Apr. 22	AQ
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)	Apr. 19	GL
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	Apr. 16	AQ
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	Apr. 16	GL
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024	Apr. 03	GL
Alvotech : Transaction of Managers and Closely Associated Persons	Mar. 22	PU
Alvotech : Transaction of Managers and Closely Associated Persons	Mar. 22	PU
Alvotech : Managers' transactions Managers' Transaction Notification J Morales 20240320	Mar. 22	PU
Alvotech : Managers' transactions Managers' Transaction Notification J McClellan 20240320	Mar. 22	PU
Alvotech Announces Increase in Number of Own Shares	Mar. 22	GL
Alvotech : Presentation Q4 2023	Mar. 20	PU
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update	Mar. 20	GL
Teva And Alvotech's Adalimumab Biosimilar Receives Interchangeable Status At FDA	Mar. 12	AQ
First High-Concentration Humira® Interchangeable, Alvotech And Teva's Simlandi®, Approved In The U.S.	Mar. 11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Alvotech Nyse

Equities

ALVO

LU2458332611

Press Releases

Filters